Literature DB >> 26322843

Association between mixed rotavirus vaccination types of infants and rotavirus acute gastroenteritis.

Anaam Mohammed1, Lilly Immergluck2, Trisha Chan Parker3, Shabnam Jain4, Traci Leong5, Evan J Anderson6, Robert C Jerris7.   

Abstract

INTRODUCTION: Rotavirus remains the leading cause of severe diarrhea in children under 5 years worldwide. In the US, Rotarix (RV1) and RotaTeq (RV5), have been associated with reductions in and severity of rotavirus disease. Studies have evaluated the impact of RV1 or RV5 but little is known about the impact of incomplete or mixed vaccination upon vaccine effectiveness.
METHODS: Case control study to examine association of combined RV1 and RV5 and rotavirus acute gastroenteritis, factoring severity of diarrheal disease. Children born after March 1, 2009 with acute gastroenteritis from three pediatric hospitals in Atlanta, Georgia were approached for enrollment. Survey was administered, stool specimen was collected, and vaccination records were obtained.
RESULTS: 891 of 1127 children with acute gastroenteritis were enrolled. Stool specimens were collected from 708 for rotavirus testing; 215 stool samples tested positively for rotavirus. Children >12 months of age were more likely to have rotavirus. Children categorized with Vesikari score of >11 were almost twice as likely to be rotavirus positive. Prior rotavirus vaccination decreased the mean Vesikari score, p<0.0001. Children with complete single type vaccination were protected against rotavirus (OR 0.21, 95% CI: 0.14-0.31, p<0.0001).
CONCLUSION: Complete rotavirus vaccination with a single vaccine type resulted in protection against rotavirus diarrhea and decrease in severity of rotavirus gastroenteritis. Incomplete rotavirus vaccination either with a single vaccine or mixed vaccination types also provided some protection.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute gastroenteritis; Pediatric; Rotavirus; Rotavirus vaccination

Mesh:

Substances:

Year:  2015        PMID: 26322843      PMCID: PMC5444377          DOI: 10.1016/j.vaccine.2015.08.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

1.  Effectiveness of rotavirus vaccine in preventing severe acute gastroenteritis in children.

Authors:  Ran D Goldman
Journal:  Can Fam Physician       Date:  2012-03       Impact factor: 3.275

Review 2.  Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011.

Authors:  Ben A Lopman; Daniel C Payne; Jacqueline E Tate; Manish M Patel; Margaret M Cortese; Umesh D Parashar
Journal:  Curr Opin Virol       Date:  2012-06-29       Impact factor: 7.090

Review 3.  Performance of rotavirus vaccines in developed and developing countries.

Authors:  Victoria Jiang; Baoming Jiang; Jacqueline Tate; Umesh D Parashar; Manish M Patel
Journal:  Hum Vaccin       Date:  2010-07

4.  Indirect protection of adults from rotavirus by pediatric rotavirus vaccination.

Authors:  Evan J Anderson; Deanna B Shippee; Melissa H Weinrobe; Melissa D Davila; Ben Z Katz; Susheel Reddy; Mary Gene Karen P Cuyugan; Samuel Y Lee; Yael M Simons; Ram Yogev; Gary A Noskin
Journal:  Clin Infect Dis       Date:  2013-01-23       Impact factor: 9.079

Review 5.  2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Jacqueline E Tate; Anthony H Burton; Cynthia Boschi-Pinto; A Duncan Steele; Jazmin Duque; Umesh D Parashar
Journal:  Lancet Infect Dis       Date:  2011-10-24       Impact factor: 25.071

6.  Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States.

Authors:  Ben A Lopman; Aaron T Curns; Catherine Yen; Umesh D Parashar
Journal:  J Infect Dis       Date:  2011-08-29       Impact factor: 5.226

7.  Impact of the introduction of rotavirus vaccine on the timeliness of other scheduled vaccines: the Australian experience.

Authors:  Brynley P Hull; Robert Menzies; Kristine Macartney; Peter B McIntyre
Journal:  Vaccine       Date:  2013-02-17       Impact factor: 3.641

8.  Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes.

Authors:  T Ruuska; T Vesikari
Journal:  Scand J Infect Dis       Date:  1990

9.  Effectiveness of vaccination with the pentavalent rotavirus vaccine in Nicaragua as determined using the screening method.

Authors:  Anna Cardellino; Shazia Khawaja; Edmundo Sánchez Cruz; T Christopher Mast
Journal:  Hum Vaccin Immunother       Date:  2013-04-09       Impact factor: 3.452

10.  Patterns of rotavirus vaccine uptake and use in privately-insured US infants, 2006-2010.

Authors:  Catherine A Panozzo; Sylvia Becker-Dreps; Virginia Pate; Michele Jonsson Funk; Til Stürmer; David J Weber; M Alan Brookhart
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

View more
  4 in total

1.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

2.  Community-level interventions for mitigating the risk of waterborne diarrheal diseases: a systematic review.

Authors:  Chisala D Meki; Esper J Ncube; Kuku Voyi
Journal:  Syst Rev       Date:  2022-04-18

3.  Differentiation between Wild-Type Group A Rotaviruses and Vaccine Strains in Cases of Suspected Horizontal Transmission and Adverse Events Following Vaccination.

Authors:  Sonja Jacobsen; Sandra Niendorf; Roswitha Lorenz; C-Thomas Bock; Andreas Mas Marques
Journal:  Viruses       Date:  2022-07-29       Impact factor: 5.818

Review 4.  A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact.

Authors:  Talia Pindyck; Jacqueline E Tate; Umesh D Parashar
Journal:  Expert Rev Vaccines       Date:  2018-07-02       Impact factor: 5.683

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.